GO:0004411 homogentisate 1,2-dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004411 describes the molecular function that catalyzes the reaction homogentisate + O2 = 4-maleylacetoacetate + H+, a step in tyrosine and phenylalanine catabolism.
• The enzyme is encoded by HGD in humans, and loss-of-function variants cause alkaptonuria, a rare inherited disorder of tyrosine metabolism [1,4].
• HGD is a non-heme Fe(II)-dependent dioxygenase that uses a cupin-like fold and a 2-His-1-Glu facial triad to bind iron and activate dioxygen [2,3].
• HGD is expressed not only in liver and kidney but also in brain, suggesting additional roles beyond peripheral tyrosine catabolism.
• Bacterial high-throughput screening systems have been developed to evaluate human HGD missense variants and to identify pharmacological chaperones for alkaptonuria [5,6].
• Catechol 1,2-dioxygenase from Pseudomonas chlororaphis UFB2 is an analogue of HGD, highlighting evolutionary and structural parallels relevant to enzyme engineering.
Description
GO:0004411, homogentisate 1,2-dioxygenase activity, is a molecular function defined by the catalysis of the reaction homogentisate + O2 = 4-maleylacetoacetate + H+. This activity is essential for the complete degradation of tyrosine and phenylalanine in mammals, and its deficiency leads to the accumulation of homogentisic acid, the hallmark of alkaptonuria [1,4]. Because the reaction is a ring-cleavage step, it is also of broad interest in microbial aromatic catabolism and in enzyme evolution studies [3,7]. Researchers study GO:0004411 to understand metabolic pathway flux, iron-dependent dioxygenase chemistry, and genotype-phenotype correlations in inherited metabolic disease [2,4]. The enzyme is a non-heme Fe(II)-dependent dioxygenase, and its catalytic mechanism involves iron coordination and oxidative cleavage of the aromatic ring of homogentisate [2,3]. Beyond liver and kidney, HGD expression has been detected in brain, raising questions about its role in the central nervous system and in neurological manifestations of alkaptonuria. Advances in structural biology and high-throughput screening have made HGD a tractable target for pharmacological chaperone development and for functional annotation of missense variants [5,6].
homogentisate 1,2-dioxygenase activity At A Glance
| GO ID | GO:0004411 |
|---|---|
| GO term | homogentisate 1,2-dioxygenase activity |
| Ontology | molecular_function |
| Synonym | homogentisate dioxygenase activity; homogentisate oxidase activity; homogentisate:oxygen 1,2-oxidoreductase (decyclizing); homogentisate oxygenase activity; homogentisic acid oxidase activity; homogentisic acid oxygenase activity; homogentisicase activity; homogentisic oxygenase activity |
| Major function | Catalysis of homogentisate + O2 = 4-maleylacetoacetate + H+ |
| Cofactor | Non-heme Fe(II) [2,3] |
| Pathway | Tyrosine and phenylalanine catabolism |
| Human gene | HGD [1,4] |
| Associated disease | Alkaptonuria [1,4] |
What Is GO:0004411?
Homogentisate 1,2-dioxygenase activity (GO:0004411) is the catalytic function that converts homogentisate and molecular oxygen into 4-maleylacetoacetate and a proton. It is a dioxygenase activity that incorporates both atoms of molecular oxygen into the substrate, cleaving the aromatic ring of homogentisate. This activity is a molecular_function in the Gene Ontology and is synonymous with homogentisate oxidase, homogentisic acid oxidase, and homogentisicase activity. The reaction is part of the tyrosine catabolic pathway, and in humans it is carried out by the HGD gene product [1,2].
Why Is homogentisate 1,2-dioxygenase activity Important in Cell Biology?
GO:0004411 is important because it represents a critical enzymatic step in tyrosine catabolism, and its dysfunction directly causes alkaptonuria, a rare metabolic disease characterized by homogentisic acid accumulation and long-term tissue damage [1,4]. The enzyme is also a model system for understanding non-heme Fe(II)-dependent dioxygenases, a large family of enzymes involved in diverse biological processes [2,3]. Because HGD missense variants are numerous and often of uncertain significance, functional assays and structural studies of this activity are essential for clinical interpretation and for developing therapeutic chaperones [4,5,6].
• Defines a key step in tyrosine and phenylalanine catabolism.
• Loss-of-function variants in HGD cause alkaptonuria, a rare inherited metabolic disorder [1,4].
• Provides a paradigm for non-heme Fe(II)-dependent dioxygenase chemistry [2,3].
• Enables genotype-phenotype correlation studies for HGD missense variants.
• Supports development of pharmacological chaperones for misfolded HGD variants.
• Allows high-throughput functional evaluation of single nucleotide polymorphisms.
• Has evolutionary links to bacterial catechol 1,2-dioxygenases.
• Is expressed in brain, suggesting roles beyond liver metabolism.
• Serves as a target for structural mimicry and enzyme engineering studies.
• Underpins diagnostic and newborn screening strategies for alkaptonuria.
Molecular Mechanism of homogentisate 1,2-dioxygenase activity
Substrate binding and iron coordination
In simple terms: The enzyme uses an iron atom to grab the substrate and oxygen.
HGD is a non-heme Fe(II)-dependent dioxygenase that binds homogentisate in a cupin-like fold. The iron is coordinated by a 2-His-1-Glu facial triad, which leaves open coordination sites for substrate and dioxygen [2,3]. Structural studies of HGD and its bacterial analogues show that the substrate binds in a hydrophobic pocket near the iron, positioning the aromatic ring for cleavage [2,3].
Dioxygen activation and ring cleavage
In simple terms: Oxygen is split and inserted into the substrate to break its ring.
After substrate binding, molecular oxygen binds to the ferrous iron and is activated, leading to incorporation of both oxygen atoms into homogentisate. This oxidative cleavage converts homogentisate to 4-maleylacetoacetate, a step that opens the aromatic ring [1,2]. The reaction is a 1,2-dioxygenation, meaning both oxygen atoms are added across the ring.
Product release and catalytic cycle
In simple terms: The product leaves and the enzyme is ready for another round.
Following cleavage, 4-maleylacetoacetate is released, and the enzyme returns to its resting state. The catalytic cycle requires the iron to remain in the ferrous state, and oxidation to ferric iron can inactivate the enzyme unless reducing agents are present. This sensitivity to oxidation is relevant for in vitro assays and for understanding disease mechanisms.
Structural determinants of activity
In simple terms: The shape of the enzyme determines whether it works properly.
The HGD monomer consists of a cupin-like domain that forms a beta-barrel, and the active site is located at the interface of two monomers in the functional homotetramer or homohexamer [2,3]. Missense variants that disrupt folding or iron coordination reduce or abolish activity, leading to alkaptonuria. Structural comparisons with bacterial catechol 1,2-dioxygenases reveal conserved catalytic residues despite low sequence identity.
Regulation and expression
In simple terms: The amount and location of the enzyme can change.
HGD expression is highest in liver and kidney, but it is also detected in brain, suggesting tissue-specific regulation. The enzyme is not known to be regulated by classical allosteric mechanisms, but its activity depends on iron availability and redox state. Inborn errors of metabolism can affect pathway flux, and pharmacological chaperones can stabilize misfolded variants.
Key Genes Involved in GO:0004411 homogentisate 1,2-dioxygenase activity
The following genes and proteins are directly or functionally associated with homogentisate 1,2-dioxygenase activity and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HGD | Encodes homogentisate 1,2-dioxygenase, the enzyme that catalyzes GO:0004411 | Primary gene for alkaptonuria; target for variant functional studies [1,4] |
| FAH | Encodes fumarylacetoacetate hydrolase, downstream of HGD in tyrosine catabolism | Deficiency causes tyrosinemia type I; used to study pathway flux |
| GSTZ1 | Encodes maleylacetoacetate isomerase, upstream of HGD | Deficiency causes maleylacetoacetate accumulation; relevant to pathway |
| TAT | Encodes tyrosine aminotransferase, upstream of HGD | Deficiency causes tyrosinemia type II; context for pathway |
| HPD | Encodes 4-hydroxyphenylpyruvate dioxygenase, upstream of HGD | Deficiency causes hawkinsinuria; pathway context |
| PAH | Encodes phenylalanine hydroxylase, upstream of tyrosine | Deficiency causes phenylketonuria; affects tyrosine flux |
| SLC16A10 | Encodes a transporter for aromatic amino acids | May influence substrate availability for HGD |
| SLC7A8 | Encodes a transporter for aromatic amino acids | May influence substrate availability for HGD |
| SLC3A1 | Encodes a transporter for amino acids | May influence substrate availability for HGD |
| SLC7A9 | Encodes a transporter for amino acids | May influence substrate availability for HGD |
| HGD (bacterial) | Homologs in bacteria, e.g., Acinetobacter | Model for structural and evolutionary studies |
| catA | Encodes catechol 1,2-dioxygenase in Pseudomonas chlororaphis UFB2 | Analogue of HGD; used for comparative enzymology |
| HGD (brain) | HGD expressed in brain tissue | Implications for neurological aspects of alkaptonuria |
| HGD variants | Missense and nonsense variants in HGD | Genotype-phenotype correlations in alkaptonuria |
| HGD (chaperone target) | Misfolded HGD variants | Pharmacological chaperone screening |
| HGD (SNP) | Single nucleotide polymorphisms in HGD | High-throughput functional evaluation |
| HGD (structural) | Cupin-like fold with Fe(II) | Structural mimicry and mechanism [2,3] |
| HGD (assay) | Recombinant HGD | Enzymatic assays for activity [5,6] |
How Is homogentisate 1,2-dioxygenase activity Regulated?
HGD activity is primarily regulated at the level of gene expression and iron availability. The enzyme is expressed in liver, kidney, and brain, and its expression may be influenced by metabolic state. The catalytic activity depends on the ferrous iron cofactor, and oxidation to ferric iron leads to inactivation, which can be reversed by reducing agents. There is no evidence for classical allosteric regulation, but pharmacological chaperones can stabilize misfolded variants and restore activity.
homogentisate 1,2-dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HGD | Alkaptonuria | HGD knockout cell line or mouse model [1,4] |
| HGD | Misfolded variant stabilization | Point-mutation knock-in of specific HGD variants |
| HGD | Neurological involvement | Brain-specific HGD knockout |
| HGD | Genotype-phenotype correlation | Overexpression of patient-derived HGD variants |
| HGD | Pharmacological chaperone screening | Bacterial high-throughput assay [5,6] |
Alkaptonuria
Alkaptonuria is an autosomal recessive disorder caused by biallelic loss-of-function variants in HGD, leading to deficiency of homogentisate 1,2-dioxygenase activity (GO:0004411) [1,4]. The accumulation of homogentisic acid causes ochronosis, a dark pigmentation of connective tissues, and leads to early-onset osteoarthritis, kidney stones, and cardiac valve disease. Genotype-phenotype studies in large cohorts have identified numerous HGD variants, including missense, nonsense, and splice-site mutations, with some correlation between residual activity and disease severity.
Neurological implications
HGD is expressed in brain, and its deficiency may have neurological consequences beyond the classical skeletal and cardiac manifestations of alkaptonuria. The presence of HGD in brain suggests a local role in tyrosine catabolism, and altered homogentisic acid levels could affect neurotransmitter metabolism. Further research is needed to determine whether neurological symptoms in alkaptonuria are directly linked to loss of GO:0004411 in the central nervous system.
Therapeutic development
Pharmacological chaperones are being developed to stabilize misfolded HGD variants and restore enzymatic activity. High-throughput screening systems using bacterial expression of human HGD have been established to evaluate missense variants and to identify small molecules that enhance activity [5,6]. These approaches aim to treat alkaptonuria by targeting the underlying enzyme deficiency rather than only managing symptoms.
From homogentisate 1,2-dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HGD cause alkaptonuria-like phenotypes? | HGD knockout cell line or mouse |
| How do specific missense variants affect enzyme activity? | Point-mutation knock-in of HGD variants [4,5] |
| Can a chaperone restore mutant HGD activity? | Knock-in of misfolded HGD with chaperone treatment |
| Where is HGD expressed and what is its role in brain? | Tagged knock-in for imaging or brain-specific KO |
| Does overexpression of HGD alter pathway flux? | Overexpression cell model |
| Can bacterial HGD analogues inform human enzyme function? | Bacterial expression of HGD homologs [3,7] |
How to Study the homogentisate 1,2-dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric assay | Enzyme activity | Kinetic characterization of HGD variants |
| High-throughput screening | Activity of many variants or drugs | Variant classification and chaperone discovery [5,6] |
| X-ray crystallography | Three-dimensional structure | Mechanistic studies and mutant modeling [2,3] |
| Site-directed mutagenesis | Effect of specific mutations | Functional validation of clinical variants |
| RT-PCR | mRNA expression | Tissue distribution |
| Immunohistochemistry | Protein localization | Tissue-specific expression |
| CRISPR knockout | Loss-of-function phenotype | Disease modeling |
| CRISPR knock-in | Specific variant expression | Genotype-phenotype studies |
Enzymatic activity assays
Homogentisate 1,2-dioxygenase activity can be measured spectrophotometrically by monitoring the decrease in homogentisate absorbance or the formation of 4-maleylacetoacetate. These assays are used to determine kinetic parameters and to evaluate the effect of missense variants. High-throughput versions have been developed in bacteria for screening large numbers of variants and small molecules [5,6].
Structural biology
X-ray crystallography and homology modeling have been used to determine the structure of HGD and its bacterial analogues, revealing the cupin fold and iron coordination [2,3]. These studies help explain how mutations affect folding and catalysis. Structural comparisons with catechol 1,2-dioxygenases provide insights into substrate specificity and evolution.
Genotype-phenotype analysis
Large cohort studies have sequenced HGD in alkaptonuria patients to identify variants and correlate them with clinical outcomes. Functional assays are needed to classify variants of uncertain significance [4,5]. Bioinformatics tools predict pathogenicity but require experimental validation.
Expression analysis
HGD expression has been studied by RT-PCR and immunohistochemistry in various tissues, including brain. These methods reveal tissue-specific distribution and may inform about local roles of the enzyme. Expression levels can also be modulated in cell models using CRISPR activation or overexpression.
How CRISPR Can Be Used to Study GO:0004411 homogentisate 1,2-dioxygenase activity
Knockout
CRISPR knockout of HGD can create cell models that lack homogentisate 1,2-dioxygenase activity, mimicking alkaptonuria. These models are useful for studying the metabolic consequences of enzyme deficiency and for testing therapeutic interventions. Knockout of HGD in mice recapitulates aspects of alkaptonuria, including ochronosis and joint damage.
Point Mutation
Point mutations identified in alkaptonuria patients can be introduced into the endogenous HGD locus using CRISPR base editing or homology-directed repair. These models allow precise evaluation of missense variants on enzyme activity and stability [4,5]. They are essential for classifying variants of uncertain significance.
Knock-in
Knock-in of tagged HGD (e.g., GFP or FLAG) enables visualization and purification of the enzyme for biochemical studies. Knock-in of patient-specific variants can create personalized models for drug testing. These models help correlate genotype with phenotype in a controlled genetic background.
Overexpression
Overexpression of wild-type or mutant HGD in cell lines can increase enzymatic activity and pathway flux, allowing study of downstream metabolites. Overexpression is also used to produce recombinant enzyme for structural and kinetic studies. It can rescue loss-of-function phenotypes in knockout backgrounds.
How EDITGENE Supports homogentisate 1,2-dioxygenase activity Research
Researchers studying homogentisate 1,2-dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in a metabolic or disease phenotype. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models that enable functional validation of HGD variants and other pathway genes.
Contact EDITGENE today to design your custom CRISPR model for homogentisate 1,2-dioxygenase activity research.
Frequently Asked Questions About homogentisate 1,2-dioxygenase activity
What is homogentisate 1,2-dioxygenase activity?
It is the enzymatic activity (GO:0004411) that catalyzes the conversion of homogentisate and oxygen to 4-maleylacetoacetate and a proton, a step in tyrosine catabolism.
What gene encodes homogentisate 1,2-dioxygenase in humans?
The HGD gene encodes the human enzyme; mutations in HGD cause alkaptonuria [1,4].
What disease is associated with homogentisate 1,2-dioxygenase deficiency?
Alkaptonuria, a rare inherited metabolic disorder characterized by homogentisic acid accumulation, ochronosis, and joint damage.
What is the reaction catalyzed by homogentisate 1,2-dioxygenase?
Homogentisate + O2 = 4-maleylacetoacetate + H+.
What cofactor does homogentisate 1,2-dioxygenase require?
It is a non-heme Fe(II)-dependent dioxygenase that requires ferrous iron for activity [2,3].
Is homogentisate 1,2-dioxygenase expressed in the brain?
Yes, HGD expression has been detected in brain tissue, suggesting roles beyond liver metabolism.
How can I study homogentisate 1,2-dioxygenase activity in the lab?
Enzymatic assays, structural biology, and CRISPR knockout or knock-in models are commonly used [2,4,5].
What are the synonyms for homogentisate 1,2-dioxygenase activity?
Synonyms include homogentisate oxidase activity, homogentisic acid oxidase activity, and homogentisicase activity.
Are there high-throughput screens for HGD variants?
Yes, bacterial high-throughput screening systems have been developed to evaluate human HGD missense variants and identify pharmacological chaperones [5,6].
What is the clinical significance of HGD genotype-phenotype correlations?
They help predict disease severity and guide personalized management in alkaptonuria.
Conclusion
Homogentisate 1,2-dioxygenase activity (GO:0004411) is a fundamental enzymatic function in tyrosine catabolism, and its deficiency causes alkaptonuria, a disease with significant morbidity. Structural and functional studies have elucidated the non-heme Fe(II)-dependent mechanism and provided a framework for understanding genotype-phenotype relationships. CRISPR-based models and high-throughput screening are accelerating the development of targeted therapies, including pharmacological chaperones, for this rare metabolic disorder.
References
- 1. Bernardini G et al.. 2024. Alkaptonuria.. Nat Rev Dis Primers 10(1):16 PMID: 38453957
- 2. Bernini A et al.. 2023. Structure-Function Relationship of Homogentisate 1,2-dioxygenase: Understanding the Genotype-Phenotype Correlations in the Rare Genetic Disease Alkaptonuria.. Curr Protein Pept Sci 24(5):380-392 PMID: 36880186
- 3. Seo PW et al.. 2025. Structural Mimicry Without Glyoxalase I Functional Convergence: A Homogentisate 1,2-Dioxygenase From Acinetobacter.. Proteins 93(12):2150-2157 PMID: 40650421
- 4. Ascher DB et al.. 2019. Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU.. Eur J Hum Genet 27(6):888-902 PMID: 30737480
- 5. Lequeue S et al.. 2025. A robust bacterial high-throughput screening assay to identify pharmacological chaperones targeting human homogentisate 1,2-dioxygenase missense variants in alkaptonuria.. Eur J Pharmacol 1005:178048 PMID: 40784658
- 6. Lequeue S et al.. 2022. A robust bacterial high-throughput screening system to evaluate single nucleotide polymorphisms of human homogentisate 1,2-dioxygenase in the context of alkaptonuria.. Sci Rep 12(1):19452 PMID: 36376482
- 7. Setlhare B et al.. 2018. Catechol 1,2-Dioxygenase is an Analogue of Homogentisate 1,2-Dioxygenase in Pseudomonas chlororaphis Strain UFB2.. Int J Mol Sci 20(1) PMID: 30586858
- 8. Bernardini G et al.. 2015. Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.. J Inherit Metab Dis 38(5):807-14 PMID: 25762405
